10-Q 1 mygn-20220630.htm 10-Q mygn-20220630
false000089992312/312022Q2P1Y00008999232022-01-012022-06-3000008999232022-07-29xbrli:shares00008999232022-06-30iso4217:USD00008999232021-12-310000899923mygn:MolecularDiagnosticTestingMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTestingMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2022-04-012022-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2022-01-012022-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-3000008999232022-04-012022-06-3000008999232021-04-012021-06-3000008999232021-01-012021-06-30iso4217:USDxbrli:shares0000899923us-gaap:CommonStockMember2020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2020-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000899923us-gaap:RetainedEarningsMember2020-12-310000899923us-gaap:NoncontrollingInterestMember2020-12-3100008999232020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100008999232021-01-012021-03-310000899923us-gaap:RetainedEarningsMember2021-01-012021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000899923us-gaap:CommonStockMember2021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000899923us-gaap:RetainedEarningsMember2021-03-310000899923us-gaap:NoncontrollingInterestMember2021-03-3100008999232021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000899923us-gaap:NoncontrollingInterestMember2021-04-012021-06-300000899923us-gaap:RetainedEarningsMember2021-04-012021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000899923us-gaap:CommonStockMember2021-06-300000899923us-gaap:AdditionalPaidInCapitalMember2021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000899923us-gaap:RetainedEarningsMember2021-06-300000899923us-gaap:NoncontrollingInterestMember2021-06-3000008999232021-06-300000899923us-gaap:CommonStockMember2021-12-310000899923us-gaap:AdditionalPaidInCapitalMember2021-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000899923us-gaap:RetainedEarningsMember2021-12-310000899923us-gaap:NoncontrollingInterestMember2021-12-310000899923us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100008999232022-01-012022-03-310000899923us-gaap:RetainedEarningsMember2022-01-012022-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000899923us-gaap:CommonStockMember2022-03-310000899923us-gaap:AdditionalPaidInCapitalMember2022-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000899923us-gaap:RetainedEarningsMember2022-03-310000899923us-gaap:NoncontrollingInterestMember2022-03-3100008999232022-03-310000899923us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000899923us-gaap:RetainedEarningsMember2022-04-012022-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000899923us-gaap:CommonStockMember2022-06-300000899923us-gaap:AdditionalPaidInCapitalMember2022-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000899923us-gaap:RetainedEarningsMember2022-06-300000899923us-gaap:NoncontrollingInterestMember2022-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2022-04-012022-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMembercountry:US2022-04-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2022-04-012022-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2022-04-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMembercountry:US2022-04-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticOtherTestingMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2022-04-012022-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2022-04-012022-06-300000899923country:USmygn:MolecularDiagnosticOtherTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2022-04-012022-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTestingMember2022-04-012022-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2022-04-012022-06-300000899923mygn:PharmaceuticalAndClinicalServicesMemberus-gaap:NonUsMember2022-04-012022-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMemberus-gaap:NonUsMember2021-04-012021-06-300000899923country:US2022-04-012022-06-300000899923us-gaap:NonUsMember2022-04-012022-06-300000899923country:US2021-04-012021-06-300000899923us-gaap:NonUsMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2022-01-012022-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMembercountry:US2022-01-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticTumorProfilingMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2022-01-012022-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2022-01-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMembercountry:US2022-01-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticAutoimmuneMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticOtherTestingMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2022-01-012022-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2022-01-012022-06-300000899923country:USmygn:MolecularDiagnosticOtherTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2022-01-012022-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTestingMember2022-01-012022-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2022-01-012022-06-300000899923mygn:PharmaceuticalAndClinicalServicesMemberus-gaap:NonUsMember2022-01-012022-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMemberus-gaap:NonUsMember2021-01-012021-06-300000899923country:US2022-01-012022-06-300000899923us-gaap:NonUsMember2022-01-012022-06-300000899923country:US2021-01-012021-06-300000899923us-gaap:NonUsMember2021-01-012021-06-3000008999232019-07-012020-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2022-04-012022-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2022-01-012022-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember2022-04-012022-06-30xbrli:pure0000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember2022-01-012022-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember2021-04-012021-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember2021-01-012021-06-300000899923us-gaap:CashMember2022-06-300000899923us-gaap:CashEquivalentsMember2022-06-300000899923us-gaap:CorporateDebtSecuritiesMember2022-06-300000899923us-gaap:MunicipalBondsMember2022-06-300000899923us-gaap:USTreasuryAndGovernmentMember2022-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300000899923us-gaap:CashMember2021-12-310000899923us-gaap:CashEquivalentsMember2021-12-310000899923us-gaap:CorporateDebtSecuritiesMember2021-12-310000899923us-gaap:MunicipalBondsMember2021-12-310000899923us-gaap:USTreasuryAndGovernmentMember2021-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000899923us-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:MoneyMarketFundsMember2022-06-300000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2022-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2022-06-300000899923us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2022-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2022-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:FairValueInputsLevel1Membermygn:ContingentConsiderationMember2022-06-300000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2022-06-300000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-06-300000899923mygn:ContingentConsiderationMember2022-06-300000899923us-gaap:FairValueInputsLevel1Member2022-06-300000899923us-gaap:FairValueInputsLevel2Member2022-06-300000899923us-gaap:FairValueInputsLevel3Member2022-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:MoneyMarketFundsMember2021-12-310000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2021-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2021-12-310000899923us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2021-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2021-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:FairValueInputsLevel1Membermygn:ContingentConsiderationMember2021-12-310000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2021-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-12-310000899923mygn:ContingentConsiderationMember2021-12-310000899923us-gaap:FairValueInputsLevel1Member2021-12-310000899923us-gaap:FairValueInputsLevel2Member2021-12-310000899923us-gaap:FairValueInputsLevel3Member2021-12-310000899923us-gaap:LeaseholdImprovementsMember2022-06-300000899923us-gaap:LeaseholdImprovementsMember2021-12-310000899923us-gaap:EquipmentMember2022-06-300000899923us-gaap:EquipmentMember2021-12-310000899923us-gaap:LeaseholdImprovementsMember2022-01-012022-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2022-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2021-12-310000899923us-gaap:RevolvingCreditFacilityMember2016-12-230000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-07-310000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-220000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-210000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-09-300000899923us-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-250000899923us-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-260000899923srt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-12-310000899923us-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMember2022-07-262022-07-260000899923us-gaap:SubsequentEventMemberus-gaap:LetterOfCreditMembermygn:AmendmentToCreditAgreementMember2022-07-262022-07-260000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-012021-06-300000899923mygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2020-04-012021-06-300000899923us-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-262022-07-260000899923us-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-262022-07-260000899923us-gaap:RevolvingCreditFacilityMember2021-01-012021-12-3100008999232016-06-300000899923mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember2022-06-300000899923us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-06-300000899923srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000899923mygn:NonEmployeeDirectorMembermygn:OptionsAndRestrictedStockUnitsMember2022-01-012022-06-300000899923us-gaap:EmployeeStockOptionMember2022-01-012022-06-300000899923srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000899923us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000899923us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2022-01-012022-06-300000899923us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2021-12-310000899923us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2022-06-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2022-06-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2021-09-232021-09-230000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2022-01-012022-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2022-04-012022-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2022-01-012022-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2022-04-012022-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2022-01-012022-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300000899923mygn:CBICIFPASettlementMembermygn:UnitedStatesAndStateOfCaliforniaMember2022-04-012022-04-010000899923mygn:CBICIFPASettlementMembermygn:RelatorMember2022-04-012022-04-010000899923srt:MinimumMember2022-06-300000899923srt:MaximumMember2022-06-300000899923mygn:WestSaltLakeCityLeaseMember2022-01-012022-03-31utr:sqft0000899923mygn:WestSaltLakeCityLeaseMember2022-03-310000899923mygn:WestSaltLakeCityLeaseMember2022-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadMyPathLLCLaboratoryMember2021-05-282021-05-280000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadMyPathLLCLaboratoryMember2021-04-012021-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadAutoimmuneAssetsMember2021-05-012021-05-010000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadRBMIncMember2021-05-212021-05-210000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadMyPathLLCLaboratoryMember2021-01-012021-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-04-012021-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-06-300000899923us-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-07-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________
FORM 10-Q
_________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to           
Commission file number:  0-26642
_________________________________________
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
_________________________________________
Delaware
(State or other jurisdiction
of incorporation or organization)
320 Wakara Way, Salt Lake City, UT
(Address of principal executive offices)
87-0494517
(I.R.S. Employer Identification No.)

84108
(Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
_________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par valueMYGNNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x
As of July 29, 2022, the registrant had 80,634,766 shares of $0.01 par value common stock outstanding.




MYRIAD GENETICS, INC.
INDEX TO FORM 10-Q
Page

3



MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in millions)
June 30,
2022
December 31,
2021
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$105.2 $258.4 
Marketable investment securities99.9 81.4 
Trade accounts receivable109.8 91.3 
Inventory15.4 15.3 
Prepaid taxes19.2 18.4 
Prepaid expenses and other current assets17.6 20.0 
Total current assets367.1 484.8 
Operating lease right-of-use assets82.9 81.8 
Long-term marketable investment securities78.5 59.0 
Property, plant, and equipment, net52.8 43.5 
Intangibles, net382.3 404.1 
Goodwill237.8 239.2 
Other assets8.8 8.3 
Total assets$1,210.2 $1,320.7 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$21.7 $29.6 
Accrued liabilities84.4 156.5 
Current maturities of operating lease liabilities13.3 13.0 
Deferred revenues0.3 5.2 
Total current liabilities119.7 204.3 
Unrecognized tax benefits27.7 27.9 
Long-term deferred taxes23.3 35.8 
Noncurrent operating lease liabilities87.4 79.3 
Other long-term liabilities4.7 5.6 
Total liabilities262.8 352.9 
Commitments and contingencies
Stockholders’ equity:
Common stock, 80.6 million and 80.0 million shares outstanding at June 30, 2022 and December 31, 2021, respectively
0.8 0.8 
Additional paid-in capital1,244.3 1,226.3 
Accumulated other comprehensive loss(8.9)(5.1)
Accumulated deficit(288.8)(254.2)
Total Myriad Genetics, Inc. stockholders’ equity947.4 967.8 
Non-controlling interest  
Total stockholders' equity947.4 967.8 
Total liabilities and stockholders’ equity$1,210.2 $1,320.7 
See accompanying notes to Condensed Consolidated Financial Statements.
4

MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (unaudited)
(in millions, except per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2022202120222021
Revenues:
Molecular diagnostic testing$179.3 $178.7 $344.2 $338.3 
Pharmaceutical and clinical services 10.7  24.2 
Total revenue179.3 189.4 344.2 362.5 
Costs and expenses:
Cost of molecular diagnostic testing49.7 48.0 97.7 92.1 
Cost of pharmaceutical and clinical services 5.7  11.9 
Research and development expense20.3 19.5 41.5 42.6 
Selling, general, and administrative expense127.1 135.2 237.7 281.6 
Goodwill and long-lived asset impairment charges 1.8 10.7 1.8 
Total costs and expenses197.1 210.2 387.6 430.0 
Operating loss(17.8)(20.8)(43.4)(67.5)
Other income (expense):
Interest income0.4 0.2 0.5 0.4 
Interest expense(0.6)(2.0)(1.5)(5.0)
Other0.1 18.8 0.1 18.7 
Total other income (expense), net(0.1)17.0 (0.9)14.1 
Loss before income tax(17.9)(3.8)(44.3)(53.4)
Income tax expense (benefit)(3.8)0.9 (9.7)(9.2)
Net loss(14.1)(4.7)(34.6)(44.2)
Net loss attributable to non-controlling interest    
Net loss attributable to Myriad Genetics, Inc. stockholders$(14.1)$(4.7)$(34.6)$(44.2)
Net loss per share:
Basic and diluted$(0.18)$(0.06)$(0.43)$(0.58)
Weighted average shares outstanding:
Basic and diluted80.4 77.2 80.3 76.6 
See accompanying notes to Condensed Consolidated Financial Statements.
5

MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
(in millions)
Three months ended
June 30,
Six months ended
June 30,
2022202120222021
Net loss attributable to Myriad Genetics, Inc. stockholders$(14.1)$(4.7)$(34.6)$(44.2)
Unrealized loss on available-for-sale debt securities, net of tax(0.8)(0.1)(2.1)(0.3)
Change in foreign currency translation adjustment, net of tax(0.5)(0.3)(1.7)(1.4)
Comprehensive loss(15.4)(5.1)(38.4)(45.9)
Comprehensive loss attributable to Myriad Genetics, Inc. stockholders$(15.4)$(5.1)$(38.4)$(45.9)
See accompanying notes to Condensed Consolidated Financial Statements.
6

MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
(in millions)
Common
stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Non-controlling interestMyriad Genetics, Inc.
Stockholders’
equity
BALANCES AT DECEMBER 31, 2020$0.8 $1,109.5 $(2.3)$(227.0)$ $881.0 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 26.0 — — — 26.0 
Stock-based payment expense— 9.0 — — — 9.0 
Net loss— — — (39.5)— (39.5)
Other comprehensive loss, net of tax— — (1.3)— — (1.3)
BALANCES AT MARCH 31, 2021$0.8 $1,144.5 $(3.6)$(266.5)$ $875.2 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 23.5 — — — 23.5 
Stock-based payment expense— 8.9 — — — 8.9 
Non-controlling interest— — — — (0.1)(0.1)
Net loss— — — (4.7)— (4.7)
Other comprehensive loss, net of tax— — (0.4)— — (0.4)
BALANCES AT JUNE 30, 2021$0.8 $1,176.9 $(4.0)$(271.2)$(0.1)$902.4 
BALANCES AT DECEMBER 31, 2021$0.8 $1,226.3 $(5.1)$(254.2)$ $967.8 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (4.8)— — — (4.8)
Stock-based payment expense— 10.1 — — — 10.1 
Net loss— — — (20.5)— (20.5)
Other comprehensive loss, net of tax— — (2.5)— — (2.5)
BALANCES AT MARCH 31, 2022$0.8 $1,231.6 $(7.6)$(274.7)$ $950.1 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 2.3 — — — 2.3 
Stock-based payment expense— 10.4 — — — 10.4 
Net loss— — — (14.1)— (14.1)
Other comprehensive loss, net of tax— — (1.3)— — (1.3)
BALANCES AT JUNE 30, 2022$0.8 $1,244.3 $(8.9)$(288.8)$ $947.4 
See accompanying notes to Condensed Consolidated Financial Statements.
7

MYRIAD GENETICS, INC.
AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)
Six months ended
June 30,
20222021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Myriad Genetics, Inc. stockholders$(34.6)$(44.2)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization25.9 35.3 
Non-cash interest expense0.4 0.8 
Non-cash lease expense5.7 6.8 
Stock-based compensation expense20.5 17.9 
Deferred income taxes(10.6)(11.5)
Unrecognized tax benefits(0.2)0.4 
Loss on inventory 6.6 
Impairment of goodwill and long-lived assets10.7 1.8 
Gain on sale of assets (32.4)
Changes in assets and liabilities:
Prepaid expenses and other current assets2.3 (4.4)
Trade accounts receivable(18.9)(12.3)
Inventory(0.1)(0.8)
Prepaid taxes(0.9)89.8 
Other assets(1.0)(2.7)
Accounts payable(8.2)8.1 
Accrued liabilities(82.9)17.4 
Deferred revenues(4.9)(9.2)
Net cash provided by (used in) operating activities(96.8)67.4 
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(13.0)(11.6)
Proceeds from sale of assets 32.5 
Purchases of marketable investment securities(85.5)(36.6)
Proceeds from maturities and sales of marketable investment securities45.2 25.0 
Net cash provided by (used in) investing activities(53.3)9.3 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans3.0 50.1 
Payment of tax withheld for common stock issued under stock-based compensation plans(5.3)(0.6)
Payment of contingent consideration recognized at acquisition (3.3)
Fees associated with refinancing of revolving credit facility (1.2)
Repayment of revolving credit facility (120.0)
Net cash used in financing activities(2.3)(75.0)
Effect of foreign exchange rates on cash and cash equivalents(0.8)(0.3)
Net increase (decrease) in cash and cash equivalents(153.2)1.4 
Cash and cash equivalents at beginning of the period258.4 117.0 
Cash and cash equivalents at end of the period$105.2 $118.4 
See accompanying notes to Condensed Consolidated Financial Statements.
8

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1.BASIS OF PRESENTATION
Myriad Genetics, Inc. and its subsidiaries (collectively, the “Company” or “Myriad”) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression or guide treatment decisions across medical specialties. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment. The Company’s corporate headquarters are located in Salt Lake City, Utah.
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2022 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. The quarter ended December 31 is generally strong as the Company typically experiences an increase in volumes from patients who have met their annual insurance deductible. In the quarters ended March 31, the Company has typically experienced a decrease in volumes due to the annual reset of patient deductibles.
Due to the ongoing COVID-19 global pandemic, including variants of COVID-19 (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2021 and early 2022 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impact of COVID-19 on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the variants of COVID-19 that have surfaced around the world, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition, or liquidity for future periods.
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period's presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.

9


2.REVENUE
Myriad primarily generates revenue by performing molecular diagnostic testing. Molecular diagnostic revenues are primarily derived from the following categories of products: Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) in February 2020, respectively. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Molecular diagnostic revenues. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.
The following table presents detail regarding the composition of the Company’s total revenue by type and by U.S. versus rest of world (“RoW”):
Three months ended June 30,
20222021
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$69.8 $9.6 $79.4 $73.8 $12.2 $86.0 
Tumor Profiling21.5 12.0 33.5 18.2 12.1 30.3 
Prenatal33.1 0.2 33.3 29.2 0.2 29.4 
Pharmacogenomics33.1  33.1 22.6  22.6 
Autoimmune   10.2  10.2 
Other   0.2  0.2 
Total molecular diagnostic revenue157.5 21.8 179.3 154.2 24.5 178.7 
Pharmaceutical and clinical services revenue   10.7  10.7 
Total revenue$157.5 $21.8 $179.3 $164.9 $24.5 $189.4 
Six months ended June 30,
20222021
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$130.5 $19.8 $150.3 $138.9 $23.2 $162.1 
Tumor Profiling41.2 24.8 66.0 42.1 19.4 61.5 
Prenatal64.8 0.4 65.2 52.8 0.3 53.1 
Pharmacogenomics62.4  62.4 40.2  40.2 
Autoimmune0.3  0.3 20.9  20.9 
Other   0.5  0.5 
Total molecular diagnostic revenue299.2 45.0 344.2 295.4 42.9 338.3 
Pharmaceutical and clinical services revenue   24.2  24.2 
Total revenue$299.2 $45.0 $344.2 $319.6 $42.9 $362.5 
10

The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
Six months ended
June 30,
(in millions)20222021
Deferred revenue - beginning balance$5.2 $32.7 
Revenue recognized(5.2)(15.5)
Prepayments0.3 6.3 
Held for sale reclassification (0.9)
Deferred revenue - ending balance$0.3 $22.6 
In accordance with ASC Topic 606, Revenue from Contracts with Customers, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date.
In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices.
The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and six months ended June 30, 2022, the Company recognized $11.7 million and $19.9 million in revenue, respectively, which resulted in a $0.11 and $0.19 impact to earnings per share, respectively, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price.
The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.
11

Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, which represents greater than 10% of its revenues. Revenues received from Medicare represented 13% of total revenue for the three and six months ended June 30, 2022, and 16% and 18% of total revenue for the three and six months ended June 30, 2021, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No payor accounted for more than 10% of accounts receivable at June 30, 2022 or December 31, 2021. The Company does not require collateral from its customers.


3.MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2022 and December 31, 2021 were as follows:
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
June 30, 2022
Cash and cash equivalents:
Cash$81.1 $— $— $81.1 
Cash equivalents24.1 — — 24.1 
Total cash and cash equivalents105.2 — — 105.2 
Available-for-sale:
Corporate bonds and notes96.5  (1.5)95.0 
Municipal bonds31.1  (0.2)30.9 
Federal agency issues21.9  (0.4)21.5 
US government securities31.3  (0.3)31.0 
Total$286.0 $ $(2.4)$283.6 
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
December 31, 2021
Cash and cash equivalents:
Cash$195.2 $— $— $195.2 
Cash equivalents63.2 — — 63.2 
Total cash and cash equivalents258.4 — — 258.4 
Available-for-sale:
Corporate bonds and notes105.7 0.1 (0.2)105.6 
Municipal bonds16.1   16.1 
Federal agency issues6.8   6.8 
US government securities11.9   11.9 
Total$398.9 $0.1 $(0.2)$398.8 
12

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2022:
(in millions)Amortized
cost
Estimated
fair value
Cash$81.1 $81.1 
Cash equivalents24.1 24.1 
Available-for-sale:
Due within one year100.5 99.9 
Due after one year through five years80.1 78.3 
Due after five years0.2 0.2 
Total$286.0 $283.6 
Additional information relating to fair value of marketable investment securities can be found in Note 4.

4.FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 13.0 years, utilizing various potential pay-out scenarios.  Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.  Changes to contingent consideration liabilities are reflected in Selling, general and administrative expense in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.
13

The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2022
Money market funds (a)$24.1 $ $ $24.1 
Corporate bonds and notes 95.0  95.0 
Municipal bonds 30.9  30.9 
Federal agency issues 21.5  21.5 
US government securities 31.0  31.0 
Contingent consideration  (7.5)(7.5)
Total$24.1 $178.4 $(7.5)$195.0 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
(in millions)Level 1Level 2Level 3Total
December 31, 2021
Money market funds (a)$63.2 $ $ $63.2 
Corporate bonds and notes 105.6  105.6 
Municipal bonds 16.1  16.1 
Federal agency issues 6.8  6.8 
US government securities 11.9  11.9 
Contingent consideration  (8.6)(8.6)
Total$63.2 $140.4 $(8.6)$195.0 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance December 31, 2021$8.6 
Change in fair value recognized in the Statement of Operations(0.5)
Translation adjustments recognized in Other comprehensive loss(0.6)
Ending balance June 30, 2022$7.5 
5.PROPERTY, PLANT AND EQUIPMENT, NET
(in millions)June 30,
2022
December 31,
2021
Leasehold improvements$41.8 $38.0 
Equipment116.6 112.4 
Property, plant and equipment, gross158.4 150.4 
Less accumulated depreciation(105.6)(106.9)
Property, plant and equipment, net$52.8 $43.5 
During the three months ended March 31, 2022, the Company ceased the use of one of its leased Salt Lake City facilities. As a result, the Company recognized a $2.1 million impairment on the property, plant and equipment associated with the lease, which consisted primarily of leasehold improvements. See Note 15 for further discussion.
Three months ended
June 30,
Six months ended
June 30,
(in millions)2022202120222021
Depreciation expense$2.8 $3.4 $5.6 $6.3 
14

6.GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2022:
(in millions)Total
Beginning balance$239.2 
Translation adjustments(1.4)
Ending balance$237.8 
Intangible Assets
Intangible assets consists of purchased licenses and technologies. The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At June 30, 2022
Purchased licenses and technologies$614.4 $(232.1)$382.3 
Total intangible assets$614.4 $(232.1)$382.3 
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At December 31, 2021
Purchased licenses and technologies$616.6 $(212.5)$404.1 
Total intangible assets$616.6 $(212.5)$404.1 
The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
June 30,
Six months ended
June 30,
(in mi